<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font17 { font-size : 17; } .font22 { font-size : 22; } .font25 { font-size : 25; } .font10 { font-size : 10; } .font27 { font-size : 27; } .font11 { font-size : 11; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font30 { font-size : 30; } .font14 { font-size : 14; } .font15 { font-size : 15; }</style>
 <body>
  <p>
   <span class="font30">and </span>
   <span class="font27">the </span>
   <span class="font25">for </span>
   <span class="font22">with </span>
   <span class="font17">treatment </span>
   <span class="font15">patients </span>
   <span class="font14">hepatitis </span>
   <span class="font13">CMV </span>
   <span class="font12">are </span>
   <span class="font12">chronic </span>
   <span class="font12">virus </span>
   <span class="font12">The </span>
   <span class="font12">therapy </span>
   <span class="font12">viral </span>
   <span class="font12">disease </span>
   <span class="font12">Med </span>
   <span class="font12">not </span>
   <span class="font12">oral </span>
   <span class="font12">DNA </span>
   <span class="font12">influenza </span>
   <span class="font12">ribavirin </span>
   <span class="font12">may </span>
   <span class="font12">used </span>
   <span class="font12">ganciclovir </span>
   <span class="font12">herpes </span>
   <span class="font12">its </span>
   <span class="font12">has </span>
   <span class="font12">acyclovir </span>
   <span class="font11">antiviral </span>
   <span class="font11">clinical </span>
   <span class="font11">daily </span>
   <span class="font11">been </span>
   <span class="font11">transplant </span>
   <span class="font11">Engl </span>
   <span class="font11">HCV </span>
   <span class="font11">adverse </span>
   <span class="font11">that </span>
   <span class="font11">orally </span>
   <span class="font11">resistance </span>
   <span class="font11">after </span>
   <span class="font11">{background </span>
   <span class="font11">active </span>
   <span class="font11">have </span>
   <span class="font11">than </span>
   <span class="font11">use </span>
   <span class="font11">drugs </span>
   <span class="font11">approved </span>
   <span class="font11">effects </span>
   <span class="font11">mg/kg </span>
   <span class="font11">most </span>
   <span class="font11">should </span>
   <span class="font11">also </span>
   <span class="font11">cytomegalovirus </span>
   <span class="font11">every </span>
   <span class="font11">Infect </span>
   <span class="font11">cidofovir </span>
   <span class="font11">those </span>
   <span class="font11">valganciclovir </span>
   <span class="font11">Dis </span>
   <span class="font11">other </span>
   <span class="font11">renal </span>
   <span class="font11">against </span>
   <span class="font11">concentrations </span>
   <span class="font11">drug </span>
   <span class="font11">margin </span>
   <span class="font11">available </span>
   <span class="font11">combination </span>
   <span class="font11">effective </span>
   <span class="font11">genotype </span>
   <span class="font11">once </span>
   <span class="font11">was </span>
   <span class="font11">{border-style </span>
   <span class="font11">HBV </span>
   <span class="font11">HSV </span>
   <span class="font11">acute </span>
   <span class="font11">genital </span>
   <span class="font11">higher </span>
   <span class="font11">interferon </span>
   <span class="font11">prevention </span>
   <span class="font11">review </span>
   <span class="font11">simplex </span>
   <span class="font11">this </span>
   <span class="font11">weeks </span>
   <span class="font11">which </span>
   <span class="font10">Oral </span>
   <span class="font10">analogue </span>
   <span class="font10">associated </span>
   <span class="font10">given </span>
   <span class="font10">px;} </span>
   <span class="font10">#ffffff;} </span>
   <span class="font10">Acyclovir </span>
   <span class="font10">excreted </span>
   <span class="font10">infection </span>
   <span class="font10">peginterferon-α </span>
   <span class="font10">risk </span>
   <span class="font10">Ganciclovir </span>
   <span class="font10">but </span>
   <span class="font10">common </span>
   <span class="font10">lamivudine </span>
   <span class="font10">more </span>
   <span class="font10">plus </span>
   <span class="font10">standard </span>
   <span class="font10">these </span>
   <span class="font10">(IV) </span>
   <span class="font10">IFN-α </span>
   <span class="font10">because </span>
   <span class="font10">hours. </span>
   <span class="font10">however, </span>
   <span class="font10">human </span>
   <span class="font10">inhibits </span>
   <span class="font10">intravenous </span>
   <span class="font10">peak </span>
   <span class="font10">recurrent </span>
   <span class="font10">respiratory </span>
   <span class="font10">such </span>
   <span class="font10">HIV </span>
   <span class="font10">SVR </span>
   <span class="font10">competitive </span>
   <span class="font10">from </span>
   <span class="font10">high </span>
   <span class="font10">immunocompromised </span>
   <span class="font10">nucleoside </span>
   <span class="font10">rate </span>
   <span class="font10">treated </span>
   <span class="font10">zoster </span>
   <span class="font10">(oral) </span>
   <span class="font10">absorbed </span>
   <span class="font10">activity </span>
   <span class="font10">including </span>
   <span class="font10">organ </span>
   <span class="font10">retinitis </span>
   <span class="font10">solid </span>
   <span class="font10">trial </span>
   <span class="font10">Valganciclovir </span>
   <span class="font10">dose </span>
   <span class="font10">half-life </span>
   <span class="font10">inhibitor </span>
   <span class="font10">liver </span>
   <span class="font10">occur </span>
   <span class="font10">patients. </span>
   <span class="font10">plasma </span>
   <span class="font10">rates </span>
   <span class="font10">serum </span>
   <span class="font10">severe </span>
   <span class="font10">tenofovir </span>
   <span class="font10">times </span>
   <span class="font10">valacyclovir </span>
   <span class="font10">viruses </span>
   <span class="font10">Chemother </span>
   <span class="font10">Clin </span>
   <span class="font10">HIV-infected </span>
   <span class="font10">However, </span>
   <span class="font10">Study </span>
   <span class="font10">compared </span>
   <span class="font10">during </span>
   <span class="font10">mechanism </span>
   <span class="font10">oseltamivir </span>
   <span class="font10">polymerase. </span>
   <span class="font10">prophylaxis </span>
   <span class="font10">protease </span>
   <span class="font10">randomized </span>
   <span class="font10">recommended </span>
   <span class="font10">who </span>
   <span class="font10">Foscarnet </span>
   <span class="font10">HSV-, </span>
   <span class="font10">Induction: </span>
   <span class="font10">Intern </span>
   <span class="font10">Maintenance: </span>
   <span class="font10">Pharmacother </span>
   <span class="font10">about </span>
   <span class="font10">bioavailability </span>
   <span class="font10">can </span>
   <span class="font10">glomerular </span>
   <span class="font10">hours </span>
   <span class="font10">include </span>
   <span class="font10">into </span>
   <span class="font10">major </span>
   <span class="font10">recipients </span>
   <span class="font10">similar </span>
   <span class="font10">treating </span>
   <span class="font10">well </span>
   <span class="font10">(eg, </span>
   <span class="font10">For </span>
   <span class="font10">High </span>
   <span class="font10">Other </span>
   <span class="font10">Valacyclovir </span>
   <span class="font10">addition </span>
   <span class="font10">development </span>
   <span class="font10">gastrointestinal </span>
   <span class="font10">generally </span>
   <span class="font10">infected </span>
   <span class="font10">infectionN </span>
   <span class="font10">inhibitors </span>
   <span class="font10">management </span>
   <span class="font10">mild </span>
   <span class="font10">multifocal </span>
   <span class="font10">nausea, </span>
   <span class="font10">occurs </span>
   <span class="font10">peginterferon-ribavirin </span>
   <span class="font10">potent </span>
   <span class="font10">preferred </span>
   <span class="font10">progressive </span>
   <span class="font10">study </span>
   <span class="font10">telbivudine </span>
   <span class="font10">twice </span>
   <span class="font10">within </span>
   <span class="font10">zanamivir </span>
   <span class="font10">Cidofovir </span>
   <span class="font10">IFN </span>
   <span class="font10">Its </span>
   <span class="font10">Treatment </span>
   <span class="font10">adefovir </span>
   <span class="font10">analogues </span>
   <span class="font10">anti-HBV </span>
   <span class="font10">cellular </span>
   <span class="font10">currently </span>
   <span class="font10">duration </span>
   <span class="font10">entecavir </span>
   <span class="font10">hemorrhagic </span>
   <span class="font10">immunodeficiency </span>
   <span class="font10">levels </span>
   <span class="font10">novel </span>
   <span class="font10">only </span>
   <span class="font10">patients, </span>
   <span class="font10">penciclovir </span>
   <span class="font10">prodrug </span>
   <span class="font10">px; </span>
   <span class="font10">recipients. </span>
   <span class="font10">replication </span>
   <span class="font10">serine </span>
   <span class="font10">systemic </span>
   <span class="font10">telaprevir </span>
   <span class="font10">treat </span>
   <span class="font10">treatment. </span>
   <span class="font10">tubular </span>
   <span class="font10">were </span>
   <span class="font10">{font-family </span>
   <span class="font10">Agents </span>
   <span class="font10">Because </span>
   <span class="font10">Drug </span>
   <span class="font10">Indicated </span>
   <span class="font10">Lactic </span>
   <span class="font10">Lamivudine </span>
   <span class="font10">RNA </span>
   <span class="font10">Ribavirin </span>
   <span class="font10">acidosis </span>
   <span class="font10">acyclovir. </span>
   <span class="font10">among </span>
   <span class="font10">days </span>
   <span class="font10">diarrhea, </span>
   <span class="font10">disoproxil </span>
   <span class="font10">due </span>
   <span class="font10">effect </span>
   <span class="font10">efficacy </span>
   <span class="font10">first </span>
   <span class="font10">font-size </span>
   <span class="font10">ganciclovir-resistant </span>
   <span class="font10">initial </span>
   <span class="font10">kidney </span>
   <span class="font10">least </span>
   <span class="font10">mutations </span>
   <span class="font10">neuraminidase </span>
   <span class="font10">neurologic </span>
   <span class="font10">placebo-controlled </span>
   <span class="font10">potential </span>
   <span class="font10">prevent </span>
   <span class="font10">preventing </span>
   <span class="font10">receiving </span>
   <span class="font10">reduced </span>
   <span class="font10">reported </span>
   <span class="font10">requires </span>
   <span class="font10">resistant </span>
   <span class="font10">significantly </span>
   <span class="font10">symptoms </span>
   <span class="font10">their </span>
   <span class="font10">therapeutic </span>
   <span class="font10">therapies </span>
   <span class="font10">therapy. </span>
   <span class="font10">type </span>
   <span class="font10">until </span>
   <span class="font10">utility </span>
   <span class="font10">viruses. </span>
   <span class="font10">when </span>
   <span class="font10">ALT </span>
   <span class="font10">Amantadine </span>
   <span class="font10">Antimicrob </span>
   <span class="font10">CHB, </span>
   <span class="font10">Famciclovir </span>
   <span class="font10">Interferons </span>
   <span class="font10">Oseltamivir </span>
   <span class="font10">PCR </span>
   <span class="font10">Pharmacokinet </span>
   <span class="font10">Rebound </span>
   <span class="font10">Resistance </span>
   <span class="font10">VZV, </span>
   <span class="font10">action </span>
   <span class="font10">all </span>
   <span class="font10">amantadine </span>
   <span class="font10">boceprevir </span>
   <span class="font10">case </span>
   <span class="font10">considered </span>
   <span class="font10">dipivoxil </span>
   <span class="font10">doses </span>
   <span class="font10">double; </span>
   <span class="font10">encephalitis </span>
   <span class="font10">especially </span>
   <span class="font10">ester </span>
   <span class="font10">famciclovir </span>
   <span class="font10">fever </span>
   <span class="font10">foscarnet </span>
   <span class="font10">hepatic </span>
   <span class="font10">herpes, </span>
   <span class="font10">immune </span>
   <span class="font10">infections </span>
   <span class="font10">infections. </span>
   <span class="font10">kinase </span>
   <span class="font10">lower </span>
   <span class="font10">marrow </span>
   <span class="font10">months </span>
   <span class="font10">multiple </span>
   <span class="font10">nephrotoxicity </span>
   <span class="font10">nucleos(t)ide </span>
   <span class="font10">often </span>
   <span class="font10">peginterferon </span>
   <span class="font10">polymerase </span>
   <span class="font10">polymerase, </span>
   <span class="font10">provides </span>
   <span class="font10">rapid </span>
   <span class="font10">recently </span>
   <span class="font10">recipientsAm </span>
   <span class="font10">reconstitution </span>
   <span class="font10">reduce </span>
   <span class="font10">resistance. </span>
   <span class="font10">rtMV/I </span>
   <span class="font10">specific </span>
   <span class="font10">substrate </span>
   <span class="font10">surveillance </span>
   <span class="font10">symptoms, </span>
   <span class="font10">syndrome </span>
   <span class="font10">target </span>
   <span class="font10">through </span>
   <span class="font10">toxicity </span>
   <span class="font10">(%) </span>
   <span class="font10">After </span>
   <span class="font10">Although </span>
   <span class="font10">Boceprevir </span>
   <span class="font10">CHB </span>
   <span class="font10">Duration </span>
   <span class="font10">Elsevier </span>
   <span class="font10">Entecavir </span>
   <span class="font10">Intravenous </span>
   <span class="font10">Penciclovir </span>
   <span class="font10">Preferred </span>
   <span class="font10">This </span>
   <span class="font10">Transplant </span>
   <span class="font10">Virol </span>
   <span class="font10">Zanamivir </span>
   <span class="font10">acyclovir, </span>
   <span class="font10">administration </span>
   <span class="font10">alfa-a </span>
   <span class="font10">anti-HIV </span>
   <span class="font10">antigenemia </span>
   <span class="font10">article </span>
   <span class="font10">border-color </span>
   <span class="font10">border-width </span>
   <span class="font10">cell </span>
   <span class="font10">concentration </span>
   <span class="font10">controlled </span>
   <span class="font10">converted </span>
   <span class="font10">disease, </span>
   <span class="font10">disease. </span>
   <span class="font10">electrolyte </span>
   <span class="font10">elimination </span>
   <span class="font10">events </span>
   <span class="font10">evidence </span>
   <span class="font10">failure </span>
   <span class="font10">filtration </span>
   <span class="font10">following </span>
   <span class="font10">function </span>
   <span class="font10">gene </span>
   <span class="font10">had </span>
   <span class="font10">highly </span>
   <span class="font10">histologic </span>
   <span class="font10">incidence </span>
   <span class="font10">inhibit </span>
   <span class="font10">inhibition </span>
   <span class="font10">kinases </span>
   <span class="font10">lamivudine, </span>
   <span class="font10">less </span>
   <span class="font10">leukoencephalopathy </span>
   <span class="font10">mainly </span>
   <span class="font10">mutation </span>
   <span class="font10">new </span>
   <span class="font10">per </span>
   <span class="font10">pharmacokinetics </span>
   <span class="font10">possess </span>
   <span class="font10">probenecid </span>
   <span class="font10">properties </span>
   <span class="font10">properties, </span>
   <span class="font10">rapidly </span>
   <span class="font10">rash </span>
   <span class="font10">resistance, </span>
   <span class="font10">resolution </span>
   <span class="font10">response </span>
   <span class="font10">results </span>
   <span class="font10">serving </span>
   <span class="font10">solid; </span>
   <span class="font10">suppression </span>
   <span class="font10">syncytial </span>
   <span class="font10">terminal </span>
   <span class="font10">thereby </span>
   <span class="font10">thymidine </span>
   <span class="font10">topical </span>
   <span class="font10">using </span>
   <span class="font10">varicella </span>
   <span class="font10">weekly </span>
   <span class="font10">{font-style </span>
   <span class="font10">{font-weight </span>
   <span class="font10">(HN) </span>
   <span class="font10">(for </span>
   <span class="font10">AIDS </span>
   <span class="font10">AIDSJ </span>
   <span class="font10">Adefovir </span>
   <span class="font10">Among </span>
   <span class="font10">Antiviral </span>
   <span class="font10">CHC </span>
   <span class="font10">CHC. </span>
   <span class="font10">COVID- </span>
   <span class="font10">Drugs </span>
   <span class="font10">EBV. </span>
   <span class="font10">Emtricitabine </span>
   <span class="font10">Epstein-Barr </span>
   <span class="font10">FDA </span>
   <span class="font10">Fanconi </span>
   <span class="font10">GroupA </span>
   <span class="font10">HBeAg-negative </span>
   <span class="font10">HBeAg-positive </span>
   <span class="font10">HHV-, </span>
   <span class="font10">HIV. </span>
   <span class="font10">Interferon-α </span>
   <span class="font10">Liver </span>
   <span class="font10">Most </span>
   <span class="font10">Nephrotoxicity </span>
   <span class="font10">One </span>
   <span class="font10">Pharmacol </span>
   <span class="font10">Risk </span>
   <span class="font10">Tenofovir </span>
   <span class="font10">Transplantsuppl </span>
   <span class="font10">United </span>
   <span class="font10">abnormalities </span>
   <span class="font10">absorption </span>
   <span class="font10">achieves </span>
   <span class="font10">acyclic </span>
   <span class="font10">adenosine </span>
   <span class="font10">alfa-b </span>
   <span class="font10">alone </span>
   <span class="font10">anemia </span>
   <span class="font10">between </span>
   <span class="font10">binding </span>
   <span class="font10">bold </span>
   <span class="font10">bone </span>
   <span class="font10">cause </span>
   <span class="font10">caused </span>
   <span class="font10">centre </span>
   <span class="font10">chain </span>
   <span class="font10">clinically </span>
   <span class="font10">cohort </span>
   <span class="font10">coinfected </span>
   <span class="font10">combined </span>
   <span class="font10">commonly </span>
   <span class="font10">concomitant </span>
   <span class="font10">confirmed </span>
   <span class="font10">courier; </span>
   <span class="font10">demonstrated </span>
   <span class="font10">depression </span>
   <span class="font10">develop </span>
   <span class="font10">discuss </span>
   <span class="font10">disorders </span>
   <span class="font10">does </span>
   <span class="font10">double-blind </span>
   <span class="font10">either </span>
   <span class="font10">elderly </span>
   <span class="font10">em; </span>
   <span class="font10">episodes </span>
   <span class="font10">even </span>
   <span class="font10">extensive </span>
   <span class="font10">fatigue, </span>
   <span class="font10">ganciclovir. </span>
   <span class="font10">gene, </span>
   <span class="font10">guanosine </span>
   <span class="font10">guided </span>
   <span class="font10">hepatitis, </span>
   <span class="font10">herpesvirus </span>
   <span class="font10">hours, </span>
   <span class="font10">hydration </span>
   <span class="font10">immunocompetent </span>
   <span class="font10">increased </span>
   <span class="font10">increases </span>
   <span class="font10">infection, </span>
   <span class="font10">infection. </span>
   <span class="font10">infections, </span>
   <span class="font10">intestinal </span>
   <span class="font10">intracellular </span>
   <span class="font10">intraocular </span>
   <span class="font10">limited </span>
   <span class="font10">long-term </span>
   <span class="font10">main </span>
   <span class="font10">mechanisms </span>
   <span class="font10">metabolism. </span>
   <span class="font10">metabolite </span>
   <span class="font10">metabolite, </span>
   <span class="font10">metabolized </span>
   <span class="font10">moderate </span>
   <span class="font10">monotherapy </span>
   <span class="font10">pain, </span>
   <span class="font10">pandemic </span>
   <span class="font10">patient </span>
   <span class="font10">peripheral </span>
   <span class="font10">phosphorylated </span>
   <span class="font10">poorly </span>
   <span class="font10">preexisting </span>
   <span class="font10">previously </span>
   <span class="font10">primary </span>
   <span class="font10">prolonged </span>
   <span class="font10">pt;} </span>
   <span class="font10">pulmonary </span>
   <span class="font10">rash. </span>
   <span class="font10">received </span>
   <span class="font10">reduces </span>
   <span class="font10">regimen </span>
   <span class="font10">relapse </span>
   <span class="font10">require </span>
   <span class="font10">resource </span>
   <span class="font10">resulted </span>
   <span class="font10">retinal </span>
   <span class="font10">ribavirin. </span>
   <span class="font10">rimantadine </span>
   <span class="font10">rtNT </span>
   <span class="font10">safety </span>
   <span class="font10">secretion. </span>
   <span class="font10">some </span>
   <span class="font10">started </span>
   <span class="font10">synthesis </span>
   <span class="font10">they </span>
   <span class="font10">treatment-naive </span>
   <span class="font10">two </span>
   <span class="font10">undergoes </span>
   <span class="font10">untreated </span>
   <span class="font10">versus </span>
   <span class="font10">virus, </span>
   <span class="font10">virus. </span>
   <span class="font10">will </span>
  </p>
 </body>
</html>
